Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma.

A. Cassoni,Usman Ali,J. Cave,S. Edwards,A. Ramsay,Robert F Miller,S. Lee

DOI: https://doi.org/10.1200/JCO.2008.18.3350

IF: 45.3

2008-11-10

Journal of Clinical Oncology

Abstract:A 51-year-old HIV-infected man presented with a 4-week history of shortness of breath, right-sided chest pain, drenching night sweats, and 5-kg weight loss. He had been diagnosed with HIV infection 23 years previously. Investigations showed anemia (hemoglobin, 9.8 g/d), an elevated C-reactive protein of 138.6 mg/L, a CD4 count of 550 cells/ L, HIV viral load of 6800 copies/ mL, and plasma Kaposi sarcoma–associated herpes virus (KSHV)/ human herpes virus 8 (HHV8) DNA of 70,000 copies/mL. A chest radiograph showed a moderately large right-sided pleural effusion. He was treated empirically for atypical pneumonia. Despite a course of antibiotics, the patient continued to complain of breathlessness. A chest radiograph 10 weeks later revealed a right-sided loculated effusion and pleural thickening. A computed tomography (CT) scan showed multiple pleural masses, the largest measuring 6.8 4.3 cm, located at the right posterolateral base, a pericardial nodule adjacent to the right atrium, a right-sided pleural effusion, and multiple small volume supraclavicular, axillary, retroperitoneal, pelvic, and inguinal adenopathy. Biopsy of the right base pleural mass identified a neoplastic infiltrate composed of large lymphoid cells with irregular pleomorphic nuclei. Many of the cells had eccentrically placed nuclei and abundant cytoplasm, giving the tumor a plasmablastic appearance (Fig 1A). Immunohistochemistry demonstrated that the tumor cells were positive for CD138 (Fig 1B), epithelial membrane antigen, and HHV8 (Fig 1C) and showed lambda light chain restriction. Epstein-Barr virus in situ hybridization was negative, and mindbomb homolog 1 showed a proliferation fraction of over 90%. The B-cell markers CD20 (Fig 1D), CD79a, and paired box gene 5 were negative. The radiologic, histologic, and serologic findings were those of HIVassociated primary effusion lymphoma (PEL). He was commenced on a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy with prophylactic intrathecal methotrexate and simultaneously started on antiretroviral therapy (ART; tenofovir, emtricitabine, and efavirenz). A CT scan after six cycles of CHOP chemotherapy showed significant disease response, with the right posterior pleural mass reduced to 4.8 3.2 cm and complete resolution of the pleural effusion. However, a positron emission tomography/CT scan assessment after eight cycles of CHOP chemotherapy showed an enlarging [F]fluorodeoxyglucose–avid pleural mass (5 5 cm). Biopsy of the posterior pleural mass showed histological appearances identical to previous biopsy, validating a diagnosis of refractory PEL. The patient started